We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer Inc. (NYSE:PFE) announced today that FDA has approved Prevnar 20™ (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae serotypes in the vaccine.
Pfizer announced Tuesday that the FDA approved Prevnar 20 to prevent invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes in adults.